A proportion of patients suffering from the autosomal recessive form of severe combined immunodeficiency have an inherited deficiency of adenosine deaminase (EC 3.5.4.4; adenosine aminohydrolase) (erythrocyte isoenzyme). We have, however, found residual adenosine deaminase activity in fibroblasts derived from four such patients. The enzyme responsible for this activity is biochemically homologous with the high-molecular-weight tissue isoenzyme of adenosine deaminase found in normal fibroblasts and tissues other than erythrocytes. The residual adenosine deaminase has an altered electrophoretic mobility, increased heat stability as compared to normals, and can be detected in fibroblasts of obligate heterozygotes. Our previous studies have indicated that the tissue and erythrocyte adenosine deaminase isoenzymes contain a common catalytic unit controlled by the gene affected in severe combined immunodeficiency with absent adenosine deaminase (erythrocyte isoenzyme). This residual adenosine deaminase therefore represents, most likely, a "mutant" enzyme in fibroblasts of patients with severe combined immunodeficiency. The data support the hypothesis that, in these patients, severe combined immunodeficiency is due to a mutation at the adenosine deaminase locus.
Severe combined immunodeficiency (SCID) is a group of inherited disorders of infancy characterized by defects of both cellular and humoral immunity, which are uniformly fatal if untreated. A deficiency of the red blood cell (RBC) enzyme, adenosine deaminase (EC 3.5.4.4; adenosine aminohydrolase) (ADA), has been reported in a proportion of patients with the autosomal recessive form of the disease (1) (2) (3) (4) . Children who are as severely affected clinically, but have the Xlinked form of the disorder, as well as approximately 50% of those with the autosomal recessive form, have normal levels of RBC-ADA (4) . Deficiency of ADA, therefore, appeafs to be a primary genetic defect, rather than one resulting from the disease state. Additionally, diminished levels of RBC-ADA, transmitted as an autoiomal Mendelian trait, are found among the family members of children with SCID and RBC-ADA deficiency (2, (4) (5) (6) . The inherited nature of the enzyme deficiency has further been confirmed by the demonstration of transmission of a "null" or "silent" gene for ADA, as determined by studies of its polymorphism in two of these families (6, 7) . It has, therefore, been suggested that the enzyme deficiency and the disease state are causally related. Alternatively, it has been suggested that the association of the two defects (RBC-ADA deficiency and SCID) could represent a frame shift mutation or a deletion fortuitously involving the locus for ADA and for a closely linked gene controlling immune differentiation (1) . The demonstration of residual enzyme activity or of a crossreacting material would favor a causal role for the enzyme deficiency in SCID.
ADA activity resides in several different isozymes in erythrocytes and in other tissues (8, 9) . RBCs contain a relatively small molecular weight (33,000) ADA which migrates rapidly on starch gel electrophoresis and exhibits a major band of activity with two secondary isozymes. Tissues other than RBCs contain, in addition to the RBC isozyme, several other forms of ADA. These additional forms of ADA are usually larger (>200,000 molecular weight), migrate more slowly during electrophoresis on starch gel, and vary in electrophoretic mobility from tissue to tissue in a characteristic manner. The electrophoretic patterns of RBC-ADA in most human populations differ according to the inheritance of two autosomal allelic genes, ADA' and ADA2, whereas the tissue isozymes reportedly do not exhibit this genetic polymorphism. In spite of these differences, we have previously demonstrated that the tissue isozymes, as well as the RBC isozyme, were deficient in tissue extracts from a child who lacked ADA activity in her RBCs (10) . Furthermore, the RBC-ADA isozyme could be converted to each of five different tissue specific isozymes of ADA by coincubation of RBC-ADA with tissue extracts which did not themselves contain detectable ADA activity (11) . This conversion of RBC-ADA to tissue isozymes presumably results from interaction with a family of previously described 140,000 molecular weight proteins present in tissues (12) . The tissue isozymes generated in vitro had the biochemical characteristics of the tissue isozymes found naturally in each of the different tissues. The genetic polymorphism of the RBC-ADA isozymes could also be detected in the tissue isozymes that had been generated in vitro (10) . These findings suggest that the tissue and RBC-ADA enzymes contain a common catalytic unit coded for by the same gene as that altered in SCID with RBC-ADA deficiency. Therefore, alterations in tissue isozyme could represent mutations at the structural locus for RBC-ADA.
We have found residual ADA activity in fibroblasts from children with SCID and RBC-ADA deficiency. This ADA activity resides in material of the same estimated molecular weight as the tissue isozyme of ADA found in normal fibroblasts, but is different in electrophoretic mobility and heat stability. Moreover, other properties of the residual ADA enzyme activity suggest that this enzyme is a product of a mutation at the structural locus for RBC-ADA.
MATERIALS AND METHODS
Fibroblasts were grown in RPMI-1640 containing 10 Fractions from Sephadex columns, as well as whole lysates, were also assayed using a previously described modification of this method (14) . Lysates were incubated with substrate for [1] [2] [3] 15 ,000 X g for 20 min; the supernatant was applied to the column and 1-ml fractions were collected and assayed for ADA activity. Gel electrophoresis and staining for enzyme activity were performed as described by Spencer et al. (8) .
For determination of rates of heat inactivation, fibroblast extracts were suspended in 0.1 M Na/PO4 pH 7.5, since lower molarities have been reported to affect the rate of heat inactivation of RBC-ADA (16) .
RESULTS
ADA activity studied in ten normal fibroblast cultures was found to vary with the degree of confluency of the fibroblasts, showing an increase in activity from "early" to "late" confluency (10.19 3 .39 compared with 16.40 + 3.32). The fibroblasts described in this report were therefore harvested at very late confluency (approximately 2-3 weeks after plating), in order to facilitate the study of any residual enzyme in mutant fibroblasts.
ADA activity was determined in fibroblasts derived from Values are given + SD; ranges are in parentheses.
nine additional normal subjects, four children affected with SCID and RBC-ADA deficiency ("mutant"), and two obligate heterozygote parents of two of the patients. The RBCs of the two obligate heterozygotes were known to contain ADA activity which was more than 2 SD below the mean ADA activity of 44 normal subjects (2) Lysates of normal and "mutant" fibroblasts were electrophoresed in starch gel and stained for adenosine deaminase activity as described in the text. Fetal calf serum (FCS) was electrophoresed in alternate channels as a marker of electrophoretic mobility, as designated by the horizontal dotted line. The normal fibroblasts (N1) exhibited two areas of ADA activity, one with the faster anodal mobility of RBC-ADA with its two minor secondary isozymes, and a slower "tissue" isozyme. (The respective molecular weights of the two isozymes were 33,000 and 260,000.) The mutant fibroblasts (Mu) exhibited only the "tissue" isozyme (260,000 molecular weight). This isozyme was faster in electrophoretic mobility than the corresponding tissue isozyme of the normal fibroblasts (both indicated in black in the diagram). Additional activity was seen on occasion in mutant fibroblasts at the origin (0) and may correspond to the very high molecular species seen in Fig. 3 (Table 2) .
Lysates of mutant and normal fibroblasts were electrophoresed in starch gel and the areas of ADA activity visualized. Normal fibroblasts showed either the RBC isozymes alone, a "tissue" isozyme alone, or both together as previously reported (9 (Fig. 1) . Occasionally, at confluence, as with the normals, a slower isozyme was also seen (Fig. 2) . This slower isozyme also migrated more rapidly than did the slow isozyme seen occasionally in normal fibroblasts.
Fibroblast extracts from two obligate heterozygotes were also examined by starch gel electrophoresis. The major portion of the ADA activity had a mobility indistinguishable from that of the usual tissue isozyme of normal fibroblasts. However, fibroblasts from heterozygotes also contained ADA activity with an increased mobility like that of the enzyme found in mutant fibroblasts (Fig. 2) .
In order to confirm that this enzyme activity did not represent endocytosed enzyme, fibroblasts were grown in _ NI Mu OH Mu  FIG. 2 . ADA activity of normal, obligate heterozygote and "mutant" fibroblasts after electrophoresis in starch gel: demonstration of "mutant" enzyme in fibroblasts from obligate heterozygotes. Lysates of fibroblasts from normals (N1), obligate heterozygotes (OH), and an affected child (Mu) were electrophoresed in starch gel and stained for ADA activity. Gels were allowed to develop for longer than usual in order to detect minor components. The normal fibroblasts exhibited only one tissue isozyme of ADA without the RBC-ADA isozyme seen in Fig. 1 . This variation in expression of RBC-ADA has been reported previously (9) . The "mutant" fibroblasts exhibited a major band of enzyme activity that had a faster electrophoretic mobility than the corresponding tissue isozyme seen in normal fibroblasts (as also seen in Fig.  1 ). The major area of enzyme activity in the obligate heterozygote (OH) was of the same electrophoretic mobility as the normal tissue isozyme, but there was an additional area of enzyme activity with the faster electrophoretic mobility of the mutant isozyme. An Fig. 1 ).
The molecular weight of normal and mutant fibroblast ADA was estimated by chromatography on Sephadex G-200 (Fig. 3) . Most normal, but no mutant fibroblasts, contained detectable ADA activity of 33,000 molecular weight, representing the RBC-ADA isozyme, as confirmed by gel electrophoresis. This activity was never detected in the mutant, but may or may not be present in the normal. Normal and mutant fibroblasts also contained a high-molecular-weight ADA activity with an estimated molecular weight of about 260,000. These values agree with previous estimates of 280,000 molecular weight for the tissue isozyme of ADA (9) . Both mutant and normal fibroblasts also contained a shoulder of activity of molecular weight of approximately 480,000.
The Michaelis constant (Km) for adenosine of the mutant and normal fibroblasts was compared. The Km for the enzyme from mutant fibroblasts was 6.47 X 10-5 M compared with a Km of 6.18 X 10-5 M for ADA (16) . Both normal and mutant fibroblast ADA showed a broad pH optimum between pH 6.5 and 8.0.
Lysates of normal and mutant fibroblasts, as well as of RBCs and lymphoid line cells, were subjected to heating at 560, and residual enzyme activity was determined at different time intervals. As seen in Fig. 4 as RBCs and lymphoid line, which contain only RBC-ADA isozymes (as determined by gel electrophoresis), were rapidly inactivated after heating at 560. Less acteristics of RBC-ADA, the residual activity resembled the tissue isozyme found in normal fibroblasts in molecular weight, Km, and pH optimum, but differed in electrophoretic mobility and heat stability. This enzyme activity detected in "mutant" fibroblasts did not appear to be endocytosed from the medium, since the level of activity, as well as its electrophoretic mobility, was independent of the level of ADA in the culture medium or the electrophoretic mobility of the exogenous ADA. We have also previously found residual, if lower, levels of ADA activity in uncultured mononuclear cells (6% of normal) (2, 6), as well as in tissues (0.02-2.0% of normal) from two patients. Residual enzyme activity has also been described by other authors in spleen and fibroblasts from two other patients (17, 18) .
We have previously demonstrated that the catalytic unit responsible for ADA activity in erythrocytes and tissues is coded by the same gene (10, 11) . Therefore the residual catalytic activity of the tissue isozyme in mutant cells is most likely a product of the same locus. The simplest explanation for the observed alteration in its electrophoretic mobility is a mutation leading to an amino-acid substitution in the catalytic unit, which results both in the observed charge difference and diminished activity. Although the tissue isozyme results from interaction of RBC-ADA with a tissue factor, a primary mutation in the tissue factor, as suggested by Van der Weyden and Kelly (19) , cannot account for the results observed here. First, the patient's RBCs, which do not contain tissue factor, demonstrated the most profound deficiency of ADA (<2% of normal). Second, we have shown here that the tissue or conversion factor present in "mutant" fibroblasts converts normal RBC-ADA to a tissue isozyme of normal electrophoretic mobility. The detection of the electrophoretically altered ADA tissue isozyme, in addition to the normal enzyme, in fibroblasts from heterozygotes lends further support to the hypothesis that the isozyme found in patients consists of a "mutant" form of the ADA catalytic unit bound to normal tissue factor.
The apparent increase in heat stability could similarly have resulted from a substitution that conferred greater stability to the molecule. However, alternative explanations for the increased heat stability must be considered. Since the tissue isozyme is normally more heat-stable than the RBC isozyme, the increased heat stability of the mutant tissue isozyme could result from a difference in interaction with the previously reported conversion factor responsible for the appearance of the tissue isozyme. Thus, a mutation resulting in a greater affinity of the catalytic unit for conversion factor could maintain the catalytic activity in the heat-stable, highmolecular-weight form. Alternatively, a mutation that gives rise to an ADA catalytic unit with a shorter half-life in the free form (RBC-ADA) would result in a greater ratio of conversion factor to free (RBC) catalytic unit, thus favoring the equilibrium for the existence of the more heat-stable tissue form.
The finding of a residual, altered or mutant ADA activity in fibroblasts from children with SCID and RBC-ADA deficiency would argue strongly against a chromosomal deletion and support a causal role for this enzyme deficiency in SCID. The pathophysiologic mechanism for this, as for many genetic disorders, is as yet uncertain. Evidence has been presented to suggest that increased concentrations of adenosine and AMP inhibit de novo pyrimidine biosynthesis (20) 
